Abstract
Over the past few years, we have achieved increasing success in the treatment of a number of autoimmune-mediated disorders affecting nerves and muscles. This success is partly attributable to the use of high-dose polyclonal intravenous immunoglobulin (IVIg), which has dramatically changed our treatment options. On the basis of results from controlled, but non-FDA-approved, clinical trials, IVIg is now the treatment of choice for Guillain–Barré syndrome, chronic idiopathic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy; IVIg offers rescue therapy for patients with rapidly worsening myasthenia gravis, and is a second-line therapy for dermatomyositis, stiff-person syndrome, and pregnancy-associated or postpartum multiple sclerosis attacks. The ability of IVIg to treat such immunologically diverse disorders effectively, coupled with its excellent safety profile, has led clinicians to use the drug more liberally, even in diseases for which the data are weak and not evidence-based and in patients with coexisting conditions. Use of IVIg for such indications can increase the risk of complications while raising the cost of the drug. Practical issues regarding dosing and frequency of infusions generate dilemmas in clinical practice. In this article, we review the current indications for IVIg treatment, address practical issues related to the use and costs of the drug, and summarize its mechanisms of action.
Key Points
-
Intravenous immunoglobulin (IVIg), a natural blood product, has an important role in the treatment of numerous neuroimmunological disorders
-
Currently, it is assumed that multiple therapeutic effects of IVIg act in concert
-
IVIg is the treatment of choice for Guillain–Barré syndrome, chronic idiopathic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy
-
IVIg offers rescue therapy in myasthenia gravis, and second-line therapy for dermatomyositis and stiff-person syndrome
-
Possible novel indications for IVIg include postpolio syndrome, narcolepsy and Alzheimer's disease
-
Increased use of IVIg might have a negative impact on availability and costs
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Imbach P et al. (1981) High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 317: 1228–1231
Gold R et al. (2003) Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurol 2: 22–32
Shevach EM (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2: 389–400
Kazatchkine MD and Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345: 747–755
Misra N et al. (2005) Intravenous immunoglobulin and dendritic cells. Clin Rev Allergy Immunol 29: 201–205
Buchwald B et al. (2002) Intravenous immunoglobulins neutralize blocking antibodies in Guillain–Barré syndrome. Ann Neurol 51: 673–680
Jacobs BC et al. (2003) Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 126: 2220–2234
Shoenfeld Y et al. (2002) Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 14: 1303–1311
Stangel M and Gold R (2004) Use of i.v. immunoglobulins in neurology: evidence-based consensus [German]. Nervenarzt 75: 801–815
Stangel M and Gold R (2005) Intravenous immunoglobulins in MS. Int MS J 12: 4–10
Achiron A et al. (2004) Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 251: 1133–1137
Keegan M et al. (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366: 579–582
Levy Y et al. (1999) A study of 20 SLE patients with intravenous immunoglobulin—clinical and serologic response. Lupus 8: 705–712
van der Meche FG and Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain–Barré syndrome. N Engl J Med 326: 1123–1129
Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome Trial Group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barré syndrome. Lancet 349: 225–230
Visser LH et al. (1995) Guillain–Barré syndrome without sensory loss (acute motor neuropathy): a subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain–Barré Study Group. Brain 118: 841–847
Hadden RD et al. (1998) Electrophysiological classification of Guillain–Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome Trial Group. Ann Neurol 44: 780–788
van Koningsveld R et al. (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain–Barré syndrome: randomised trial. Lancet 363: 192–196
Raphael JC et al. (2001) Intravenous immune globulins in patients with Guillain–Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71: 235–238
Hahn AF et al. (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy—a double-blind, placebo-controlled, cross-over study. Brain 119: 1067–1077
Hughes R et al. (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50: 195–201
Mendell JR et al. (2001) Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56: 445–449
Dyck PJ et al. (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36: 838–845
Federico P et al. (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55: 1256–1262
Leger JM et al. (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124: 145–153
Van den Berg LH et al. (1995) Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59: 248–252
Terenghi F et al. (2004) How long is IVIg effective in multifocal motor neuropathy? Neurology 62: 666–668
Comi G et al. (2002) A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 249: 1370–1377
Dalakas MC et al. (1996) A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 40: 792–795
Renaud S et al. (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27: 611–615
Gajdos P et al. (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 41: 789–796
Gajdos P et al. (2005) Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin—a randomized double-blind clinical trial. Arch Neurol 62: 1689–1693
Dalakas MC et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329: 1993–2000
Dalakas MC et al. (1997) Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48: 712–716
Walter M et al. (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247: 22–28
Sommer C et al. (2005) Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 365: 1406–1411
Dalakas MC et al. (2001) High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 345: 1870–1876
Du Y et al. (2001) Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 57: 801–805
Dodel R et al. (2002) Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 52: 253–256
Dodel RC et al. (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75: 1472–1474
Gonzalez H et al. (2002) Prior poliomyelitis—evidence of cytokine production in the central nervous system. J Neurol Sci 205: 9–13
Gonzalez H et al. (2004) Prior poliomyelitis—IVIg treatment reduces proinflammatory cytokine production. J Neuroimmunol 150: 139–144
Gonzalez H et al. (2006) Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol 5: 493–500
Siegel JM and Boehmer LN (2006) Narcolepsy and the hypocretin system—where motion meets emotion. Nat Clin Pract Neurol 2: 548–556
Dauvilliers Y et al. (2004) Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56: 905–908
Dauvilliers Y (2006) Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Ann Neurol 60: 153
Stangel M et al. (2003) Side effects of intravenous immunoglobulins in neurological autoimmune disorders—a prospective study. J Neurol 250: 818–821
Dalakas MC (1999) Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 22: 1479–1497
Voltz R et al. (1996) Reversible encephalopathy with cerebral vasospasm in a Guillain–Barré syndrome patient treated with intravenous immunoglobulin. Neurology 46: 250–251
Jarius S (2002) Intravenous immunoglobulin preparations contain atypical antineutrophil antibodies and cause an oxidative burst in neutrophils. J Neurol 249 (Suppl 1): I/58
Katz U and Schoenfeld Y (2005) Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 14: 802–808
Okuda D et al. (2003) Arterial thrombosis induced by IVIg and its treatment with tPA. Neurology 60: 1825–1826
Caress JB et al. (2003) The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 60: 1822–1824
Orbach H et al. (2005) Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 29: 173–184
Ahsan N et al. (1996) Acute renal failure following immunoglobulin therapy. Am J Nephrol 16: 532–536
Ahsan N et al. (1994) Intravenous immunoglobulin-induced osmotic nephrosis. Arch Int Med 154: 1985–1987
Dalakas MC (1997) Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 126: 721–730
Spath PJ et al. (2001) Production, tolerability and virus safety of intravenous immunoglobulins [German]. In Immunoglobulins in Clinical Neurology, 1–42 (Ed Berlit P) Darmstadt: Steinkopff Verlag
Dalakas MC: Practical guidelines in the administration of IVIg in neurological diseases. J Neurol Sci, in press
McCrone P et al. (2003) Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 10: 687–694
Hanchett M et al. (2004) Current issues in immunoglobulin therapies. J Assoc Vasc Access 9: 156–158
Reid B (online 22 August 2005) IVIG shortage driving patients to hospitals [http://www.drugtopics.com/drugtopics/article/articleDetail.jsp?id=175684&searchString=ivig%20shortage] (accessed 19 October 2006)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Gold, R., Stangel, M. & Dalakas, M. Drug Insight: the use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues. Nat Rev Neurol 3, 36–44 (2007). https://doi.org/10.1038/ncpneuro0376
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0376
This article is cited by
-
Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review
Journal of Neurology (2021)
-
Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy
Neurotherapeutics (2021)
-
Konsensuspapier zum Einsatz der therapeutischen Apherese in der Neurologie
DGNeurologie (2019)
-
Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation
Journal of Neuroinflammation (2016)
-
Infektiologische Risiken in der Multiple-Sklerose-Therapie durch infundierbare Immuntherapeutika
Der Nervenarzt (2015)